» Articles » PMID: 22015769

Transglutaminase 2: a Molecular Swiss Army Knife

Overview
Specialties Biochemistry
Biophysics
Date 2011 Oct 22
PMID 22015769
Citations 122
Authors
Affiliations
Soon will be listed here.
Abstract

Transglutaminase 2 (TG2) is the most widely distributed member of the transglutaminase family with almost all cell types in the body expressing TG2 to varying extents. In addition to being widely expressed, TG2 is an extremely versatile protein exhibiting transamidating, protein disulphide isomerase and guanine and adenine nucleotide binding and hydrolyzing activities. TG2 can also act as a protein scaffold or linker. This unique protein also undergoes extreme conformational changes and exhibits localization diversity. Being mainly a cytosolic protein; it is also found in the nucleus, associated with the cell membrane (inner and outer side) and with the mitochondria, and also in the extracellular matrix. These different activities, conformations and localization need to be carefully considered while assessing the role of TG2 in physiological and pathological processes. For example, it is becoming evident that the role of TG2 in cell death processes is dependent upon the cell type, stimuli, subcellular localization and conformational state of the protein. In this review we discuss in depth the conformational and functional diversity of TG2 in the context of its role in numerous cellular processes. In particular, we have highlighted how differential localization, conformation and activities of TG2 may distinctly mediate cell death processes.

Citing Articles

Phenethylaminylation: Preliminary Evidence for the Covalent Transamidation of Psychedelic Phenethylamines to Glial Proteins using 3,5-Dimethoxy-4-(2-Propynyloxy)-Phenethylamine as a Model Compound.

Rangan R, Petty R, Acharya S, Emmitte K, do Valle R, Lam C bioRxiv. 2025; .

PMID: 40027829 PMC: 11870397. DOI: 10.1101/2025.02.13.638188.


The Search for a Universal Treatment for Defined and Mixed Pathology Neurodegenerative Diseases.

ODay D Int J Mol Sci. 2025; 25(24.

PMID: 39769187 PMC: 11678063. DOI: 10.3390/ijms252413424.


Pharmacological Inhibition of Astrocytic Transglutaminase 2 Facilitates the Expression of a Neurosupportive Astrocyte Reactive Phenotype in Association with Increased Histone Acetylation.

Delgado T, Emerson J, Hong M, Keillor J, Johnson G Biomolecules. 2025; 14(12.

PMID: 39766301 PMC: 11673777. DOI: 10.3390/biom14121594.


Expression of transglutaminase-2 (TGM2) in the prognosis of female invasive breast cancer.

Blows F, Ali H, Cope W, Pharoah P, Pike C, Provenzano E BJC Rep. 2024; 2(1):5.

PMID: 39516660 PMC: 11523935. DOI: 10.1038/s44276-023-00030-w.


Distinct conformational states enable transglutaminase 2 to promote cancer cell survival versus cell death.

Aplin C, Zielinski K, Pabit S, Ogunribido D, Katt W, Pollack L Commun Biol. 2024; 7(1):982.

PMID: 39134806 PMC: 11319651. DOI: 10.1038/s42003-024-06672-x.


References
1.
Tee A, Marshall G, Liu P, Xu N, Haber M, Norris M . Opposing effects of two tissue transglutaminase protein isoforms in neuroblastoma cell differentiation. J Biol Chem. 2009; 285(6):3561-3567. PMC: 2823496. DOI: 10.1074/jbc.M109.053041. View

2.
De Laurenzi V, Melino G . Gene disruption of tissue transglutaminase. Mol Cell Biol. 2000; 21(1):148-55. PMC: 88788. DOI: 10.1128/MCB.21.1.148-155.2001. View

3.
Akimov S, Belkin A . Cell surface tissue transglutaminase is involved in adhesion and migration of monocytic cells on fibronectin. Blood. 2001; 98(5):1567-76. DOI: 10.1182/blood.v98.5.1567. View

4.
Jang G, Jeon J, Cho S, Shin D, Kim C, Jeong E . Transglutaminase 2 suppresses apoptosis by modulating caspase 3 and NF-kappaB activity in hypoxic tumor cells. Oncogene. 2009; 29(3):356-67. DOI: 10.1038/onc.2009.342. View

5.
Boros S, Ahrman E, Wunderink L, Kamps B, de Jong W, Boelens W . Site-specific transamidation and deamidation of the small heat-shock protein Hsp20 by tissue transglutaminase. Proteins. 2005; 62(4):1044-52. DOI: 10.1002/prot.20837. View